Literature DB >> 11841407

CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia.

Patrice Chevallier1, Dominique Penther, Hervé Avet-Loiseau, Nelly Robillard, Norbert Ifrah, Béatrice Mahé, Mohamed Hamidou, Hervé Maisonneuve, Philippe Moreau, Henri Jardel, Jean Luc Harousseau, Régis Bataille, Richard Garand.   

Abstract

CD38 expression and chromosomal abnormalities are novel prognostic factors in chronic lymphocytic leukaemia (CLL). However, their value remains undetermined. CD38 was evaluated in 123 patients and chromosomal aberrations in 111 cases with fluorescence in situ hybridization (FISH). CD38 expression was found in 27% of the cases. In addition, seven out of 32 CD38- patients became CD38+ during evolution of the disease. Chromosomal abnormalities included isolated 13q deletion (40%), 12q trisomy (14%), 11q deletion (without 17p deletion) (14%) and 17p deletion (7%). CD38 expression was significantly associated with Binet stages B and C, atypical morphology and 11q deletion. On univariate analysis of survival estimates, advanced Binet stages, CD38+ phenotype, atypical morphology and 11q or 17p deletions were associated with shorter event-free survival (EFS), treatment-free interval (TFI) and overall survival (OS). Multivariate analysis identified both Binet stages and CD38 as independent prognostic factors with regard to EFS and TFI. However, CD38 appeared as an independent factor for OS when restricted to Binet stage A. Chromosomal aberrations were re-evaluated during evolution in 31 cases. The 17p deletion was the most frequent new chromosomal abnormality (35%) and significantly associated with death (64%). In conclusion, CD38 expression and secondary 17p deletion are important poor prognostic indicators, especially in Binet stage A CLL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11841407     DOI: 10.1046/j.0007-1048.2001.3205.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate.

Authors:  Natarajan Muthusamy; Heather Breidenbach; Leslie Andritsos; Joseph Flynn; Jeffrey Jones; Asha Ramanunni; Xiaokui Mo; David Jarjoura; John C Byrd; Nyla A Heerema
Journal:  Cancer Genet       Date:  2011-02

3.  Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia.

Authors:  Petra Korać; Radmila Ajduković; Mirjana Mariana Kardum Paro; Branimir Jaksić; Mara Dominis
Journal:  J Mol Histol       Date:  2009-03-07       Impact factor: 2.611

Review 4.  Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia.

Authors:  Russell A Higgins; Shelly R Gunn; Ryan S Robetorye
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

5.  B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.

Authors:  Elena Sabattini; Rocio Orduz; Cristina Campidelli; Pier Luigi Zinzani; Vincenzo Callea; Simona Zupo; Giovanna Cutrona; Fortunato Morabito; Manlio Ferrarini; Stefano Pileri
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

6.  CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells.

Authors:  Xiangning Bu; Jiro Kato; Julie A Hong; Maria J Merino; David S Schrump; Frances E Lund; Joel Moss
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

Review 7.  Prognostic factors in chronic lymphocytic leukemia-what do we need to know?

Authors:  Paula Cramer; Michael Hallek
Journal:  Nat Rev Clin Oncol       Date:  2010-10-19       Impact factor: 66.675

Review 8.  Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review.

Authors:  Prerna Mewawalla; Sunita Nathan
Journal:  Ther Adv Hematol       Date:  2014-10

9.  Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.

Authors:  Rachel L Sargent; Fiona E Craig; Steven H Swerdlow
Journal:  Int J Clin Exp Pathol       Date:  2009-06-16

10.  De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia.

Authors:  Amro M S El-Ghammaz; Essam Abdelwahed; Nevine N Mostafa; Dina A Mansour
Journal:  Clin Exp Med       Date:  2014-10-10       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.